Mavaei Maryamosadat, Farokhi Simin, Yousefi Mohammad Hasan, Fakouri Arshia, Shadab Alireza, Abdolmohammadi Mohammad Hossein, Fallahian Faranak, Afkhami Hamed
Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Front Oncol. 2025 May 13;15:1533065. doi: 10.3389/fonc.2025.1533065. eCollection 2025.
Cancer is a complex and heterogeneous disease that often requires multifaceted treatment strategies to achieve optimal therapeutic outcomes. Given the limitations of single-agent therapies, particularly in the face of intricate biological signaling networks and treatment resistance, there is a growing need for combinatory approaches. This article presents a novel hypothesis: the simultaneous use of ribosome-inactivating proteins (RIPs) and mesenchymal stem cells (MSCs) or MSC-derived extracellular vesicles (EVs) in cancer treatment. RIPs, with their potent cytotoxic properties, can target tumor cells effectively, while MSCs, known for their tumor-homing abilities and regenerative potential, can serve as delivery vehicles, potentially enhancing the targeting precision and reducing the systemic toxicity of RIPs. This hypothesis explores the synergistic potential of combining these two therapeutic modalities, leveraging the advantages of both techniques to create a more effective cancer treatment strategy. By combining RIPs' ability to inhibit protein synthesis with MSCs or MSC-derived EVs' capability to modulate the tumor microenvironment and deliver therapeutic agents. This approach offers a promising avenue for overcoming cancer's inherent complexity. However, challenges remain, such as optimizing dosing protocols, addressing safety concerns, and ensuring efficient drug delivery. Future research and clinical trials are necessary to validate this combination as a viable cancer therapy.
癌症是一种复杂的异质性疾病，通常需要多方面的治疗策略才能实现最佳治疗效果。鉴于单药治疗的局限性，尤其是面对复杂的生物信号网络和治疗耐药性时，对联合治疗方法的需求日益增长。本文提出了一个新的假设：在癌症治疗中同时使用核糖体失活蛋白（RIPs）和间充质干细胞（MSCs）或MSC衍生的细胞外囊泡（EVs）。RIPs具有强大的细胞毒性，能够有效靶向肿瘤细胞，而MSCs以其肿瘤归巢能力和再生潜力而闻名，可作为递送载体， potentially增强RIPs的靶向精度并降低其全身毒性。这一假设探讨了将这两种治疗方式相结合的协同潜力，利用两种技术的优势来创建更有效的癌症治疗策略。通过将RIPs抑制蛋白质合成的能力与MSCs或MSC衍生的EVs调节肿瘤微环境和递送治疗药物的能力相结合。这种方法为克服癌症固有的复杂性提供了一条有前景的途径。然而，挑战依然存在，如优化给药方案、解决安全问题以及确保高效的药物递送。未来的研究和临床试验对于验证这种联合作为一种可行的癌症治疗方法是必要的。
